Biogen price target lowered to $187 from $241 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Biogen (BIIB) to $187 from $241 and keeps a Buy rating on the shares. The firm thinks that despite the Kisunla competition, Leqembi might see a continuous uptake which might be bolstered by the maintenance and subcutaneous dosing. H.C. Wainwright dropped the price target after updating its discount rate across its coverage to better reflect the current macro environment.